David C Dalgarno

This inventor holds 25 USPTO granted patents and 27 published patent applications, plus 5 CIPO patents and 9 EPO patents, primarily in Kinase Inhibitors. Top assignees: Ariad Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited. Active years: 2002-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David C Dalgarno. Retrieved from https://idiyas.com/inventor/david-c-dalgarno

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 27)

% Patents Active = 72.0

CIPO Patents = 5 (Patent Applications = 4)

EPO Patents = 9 (Patent Applications = 22)

Average Co-Inventor Count = 8.6

ph-index = 11

Forward Citations = 251(Granted Patents)

Location History:

Cambridge, MA (US) (2021 - 2023)
Brookline, MA (US) (2002 - 2024)

Company Filing History:

24 out of 69

Ariad Pharmaceuticals, Inc.

patents

1 out of 1,226

Takeda Pharmaceutical Company Limited

patents

Years Active: 2002-2024

Loading Chart...

Areas of Expertise:

Heteroaryl Compounds

Kinase Inhibition

Aminothiazole Compounds

c-Kit Inhibitors

EGFR-driven Cancers

Choline Kinase Inhibitors

Acetylenic Derivatives

Phosphorus Derivatives

Azaindole Derivatives

Oral Formulations

Monocyclic Heteroaryl Compounds

Proton Pump Inhibitors

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11958850 - Heteroaryl compounds for kinase inhibition (2024-04-16),

2. 11753404 - Aminothiazole compounds as c-Kit inhibitors (2023-09-12),

3. 11117883 - Benzimidazole compounds as c-Kit inhibitors (2021-09-14),

4. 11001580 - Aminothiazole compounds as c-Kit inhibitors (2021-05-11),

5. 10227342 - Heteroaryl compounds for kinase inhibition (2019-03-12),

6. 9834571 - Compounds for inhibiting cell proliferation in EGFR-driven cancers (2017-12-05),

7. 9834521 - Choline kinase inhibitors (2017-12-05),

8. 9834518 - Compounds for inhibiting cell proliferation in EGFR-driven cancers (2017-12-05),

9. 9796712 - Heteroaryl compounds for kinase inhibition (2017-10-24),

10. 9278971 - Substituted acetylenic pyrazolo[1,5-a]pyrimidines as kinase inhibitors (2016-03-08),

11. 9273077 - Phosphorus derivatives as kinase inhibitors (2016-03-01),

12. 9090561 - Acetylenic heteroaryl compounds (2015-07-28),

13. 9029533 - Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors (2015-05-12),

14. 9012462 - Phosphorous derivatives as kinase inhibitors (2015-04-21),

15. 8912330 - Azaindole derivatives as kinase inhibitors (2014-12-16),

Title: The Innovative Journey of David C Dalgarno

Introduction: David C Dalgarno is a renowned inventor based in Brookline, MA (US) known for his groundbreaking contributions to various fields.

Latest Patents: David C Dalgarno holds several patents in the areas of technology, healthcare, and consumer products, showcasing his diverse range of expertise.

Career Highlights: With a career spanning over two decades, David C Dalgarno has worked with leading companies to develop cutting-edge solutions that have revolutionized industries.

Collaborations: Throughout his career, David C Dalgarno has collaborated with top researchers, engineers, and designers to bring his innovative ideas to life, resulting in successful products and technologies.

Conclusion: David C Dalgarno's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and entrepreneurs.

Profile summary based on public USPTO records.